Microdosing GLP-1 drugs gains attention as lower-cost weight-loss strategy
Users and researchers explore smaller, more frequent doses of Wegovy and Zepbound to reduce side effects and costs.
What to know
- Microdosing GLP-1 medications involves taking smaller, more frequent doses rather than standard weekly injections, reportedly reducing side effects and medication costs.
- The practice borrows terminology from the psychedelic community and is gaining attention among users seeking alternatives to standard dosing.
- Medical professionals including Harvard-affiliated researchers are beginning to discuss and examine the trend, though evidence on safety and efficacy remains limited.
Dr. Chris Thompson Professor of Medicine, Harvard Medical School
How it unfolded 2 developments, newest first · click a bar or a number to jump articlesposts
-
2
Huberman Lab highlights microdosing trend and researcher perspective
Andrew Huberman's lab account posted about the microdosing trend, noting it reduces side effects and costs, and shared commentary from Dr. Chris Thompson, a Harvard Medical School professor of medicine.
“"Microdosing" — a term taken from the psychedelic community, has become a popular way for people to take GLP meds with fewer side effects, and continually.”
— @hubermanlab -
“Microdosing” — a term taken from the psychedelic community, has become a popular way for people to take GLP meds with fewer side effects, and continually. Not to mention reduced cost. Dr Chris Thompson MD, Professor of Medicine at Harvard Medical School explains.
-
- 2 days quiet
-
1
Health outlets examine microdosing approach for GLP-1 medications
Multiple health publications including Healthline and Livemint published articles exploring whether microdosing GLP-1 drugs like Wegovy and Zepbound could help with weight loss.
-
first by Livemint, 5d ago
-
first by Healthline, 5d ago
-